T-DM1 reduced risk of invasive disease events and death compared with trastuzumab in HER2-positive early breast cancer with ...
Dr. Debu Tripathy breaks down the FDA approval of Enhertu in unresectable or metastatic HR-positive, HER2-low or -ultralow ...
Ado-trastuzumab emtansine led to improved overall survival and invasive disease–free survival over trastuzumab in patients ...
Dr. Debu Tripathy discussed the importance of understanding the distinctions between HER2-low and HER2-ultralow breast cancer.
San Antonio Breast Cancer Symposium 2024 provided multiple updates in the field of HER2-positive breast cancer, including novel treatments, new treatment regimens and more.See Healio’s highlights in H ...
FDA approves vimseltinib for tenosynovial giant cell tumor and a triplet for R/R LBCL, plus the latest from ASCO GU 2025.
Two sessions into that, my HER2 test came back positive. My oncologist added in Herceptin (trastuzumab) and Perjeta (pertuzumab), which he called "anti-HER2 therapy." Chemotherapy went from $1,400 ...
Biologic medicines have transformed treatment for numerous chronic and life-threatening conditions such as cancer, ...
Ridgefield, Conn., U.S., and Ingelheim, GermanyZongertinib would be the first orally administered, targeted therapy for previously treated ...
and who commence therapy within 12 months of completing trastuzumab-based therapy. [2,3] For these women, the five-year risk ...
Holdings announced its plans to advance the development of its proprietary Antibody Drug Conjugate (ADC) platform ...